We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP.
- Authors
Küçükyurt, Selin; Eşkazan, Tuğçe; Ayer, Mesut; Kılıçkıran Avcı, Burçak; Hatemi, İbrahim; Eşkazan, Ahmet Emre
- Abstract
Pleural effusion (PE) is the most frequent pulmonary complication of dasatinib, a tyrosine kinase inhibitor (TKI). Concurrent pericardial effusions have been reported in about one-third of the cases. In this study, we aimed to investigate ascites generation in chronic-phase chronic myeloid leukemia (CML-CP) patients developing PE under dasatinib. We conducted a cross-sectional study to evaluate whether pericardial effusion and ascites accompany PE in CML-CP patients treated with dasatinib. For this purpose, consecutive patients with CML-CP who developed PE under dasatinib therapy have been evaluated with chest X-ray, transthoracic echocardiography, and abdominal ultrasonography. There were seven patients, and the median age was 50 years (range, 31–73 years). Most of patients were male (n=5). All patients received imatinib as first-line TKI. Six patients received dasatinib following imatinib failure in second line. The median duration from dasatinib initiation to PE generation was 58 months (range, 8–135 months). Consequently, four patients had grade 1 pericardial effusion, and no patient had ascites. In our small study, dasatinib-related PE was associated with low-grade pericardial effusion but no ascites. There are hypothetical explanations of this phenomenon including the simultaneous activation/inhibition of kinases; however, more research needs to be performed on this topic.
- Subjects
PLEURAL effusions; DASATINIB; ECHOCARDIOGRAPHY; CHRONIC myeloid leukemia; ULTRASONIC imaging
- Publication
Pleura & Peritoneum, 2024, Vol 9, Issue 1, p39
- ISSN
2364-7671
- Publication type
Article
- DOI
10.1515/pp-2023-0016